SRSF2 and myelodysplastic syndrome: Our results suggest that modulating the cytoskeleton by RKI-1447 and possibly other microtubule modifiers can take advantage of the abnormal cytoskeleton induced by SRSF2 Mut and open new ways to treat AML/MDS and pre-leukemia.